• Explore /
  • Poster
  • / Real-world overall survival (OS) and time to therapy discontinuation (TTD) of patients (pts) with mCRPC treated with second-generation novel hormonal therapies (NHT) associated with tissue-based comprehensive genomic profiling (CGP).

Real-world overall survival (OS) and time to therapy discontinuation (TTD) of patients (pts) with mCRPC treated with second-generation novel hormonal therapies (NHT) associated with tissue-based comprehensive genomic profiling (CGP).

Abstract Poster

Authors

Ryon Graf

Ryon Graf

Foundation Medicine, Cambridge, MA

Ryon Graf , Russell Madison , Ole Gjoerup , Lei Zhong , Samantha Morley , Sunandini Chopra , Leah Comment , Virginia Fisher , Gerald Li , Kimberly McGregor , Alexa Betzig Schrock , Hanna Tukachinsky , Tamara Snow , Cheryl D. Cho-Phan , Akshay Swaminathan , Jeffrey S. Ross , Margaret Elizabeth McCusker , Amado J. Zurita , Jeffrey Venstrom

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Prostate Cancer - Advanced Disease

Track

Prostate Cancer - Advanced

Sub Track

Translational Research

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr 142)

DOI

10.1200/JCO.2021.39.6_suppl.142

Abstract #

142

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Anis Hamid

Poster

2023 ASCO Genitourinary Cancers Symposium

<span color-m="#000000" font-m="Calibri" size-m="10pt">Clinical and molecular features of </span><em><span color-m="#000000" font-m="Calibri" size-m="10pt" italic-m="true">ATM</span></em><span color-m="#000000" font-m="Calibri" size-m="10pt"> and </span><em><span color-m="#000000" font-m="Calibri" size-m="10pt" italic-m="true">BRCA2 </span></em><span color-m="#000000" font-m="Calibri" size-m="10pt">mutations in metastatic prostate cancer.</span>

Clinical and molecular features of ATM and BRCA2 mutations in metastatic prostate cancer.

First Author: Xiaolei Shi

First Author: Fadi Taza

Poster

2021 Genitourinary Cancers Symposium

5-hydroxymethylcytosine as a liquid biopsy biomarker in mCRPC.

5-hydroxymethylcytosine as a liquid biopsy biomarker in mCRPC.

First Author: Martin Sjöström